Latest News:
Follow us

Home > Past Conferences > Drug Discovery Re-Invented

Drug Discovery Re-Invented

Emerging Role of Biotechs, Academics and Non-Profits

16 Oct 13 - 19 Oct 13

Bill Kinney
Dr. Bill Kinney
Director of Medicinal Chemistry, Blumberg Institute & IteraMed
Charles H. Reynolds
Dr. Charles H. Reynolds
President / CSO, Gfree Bio LLC / Small Molecule PPI Mimics

The conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.

Key Sessions include:

  1. Discovery Re-Invented
  2. Novel Pharma Approaches
  3. Collaborative Drug Discovery
  4. Natural Products
  5. Structure, Modelling and Informatics
  6. Biologics and Non-traditional Therapeutics
  7. Discovery Technologies
  8. Exhibit

Dr. William A. Kinney's Bio:

Dr. Kinney began his industrial career in the CNS group at Wyeth, where he invented the cyclobutenedione-containing NMDA antagonist perzinfotel that progressed to phase II clinical trials for pain.  At Magainin Pharmaceuticals, he directed projects on trodusquemine (phase II, obesity) and squalamine (phase II, eye disease), two shark-derived natural products.  In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications.  He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.  Currently, Dr. Kinney is a faculty member within the Institute for Hepatitis and Virus Research.  He directed the technical feasibility, business plan development, and logistics for the donation of the former Merck Research Laboratories Natural Product Collection to the IHVR. He also initiated a structure based drug design project on a new anti-viral target in collaboration with Prof. Peter Katsikis at Drexel University to develop PI3K p110d kinase inhibitors that block host cell signaling pathways required for influenza infection and pathogenesis.  He is an adjunct faculty member atDrexelUniversityand Founder of IteraMed, a company focused on internal and out-sourced organic synthesis, consulting, and drug discovery.  His scientific contributions include 70 publications, invited lectures, and oral presentations and inventorship on 37 issued U.S. patents. 

Dr. Charles H. Reynolds' Bio:

Dr. Reynolds is currently President of GFree, LLC, a structure-based drug discovery company based in suburban Philadelphia.  He is an expert in the areas of computational chemistry, structure-based design, and drug discovery with more than 25 years of experience.  Dr. Reynolds is also a Director on the Advisory Board of Quantum Bio, Inc. and an adjunct professor at the Pennsylvania Drug Discovery Institute.  Previously he was Senior Director and Head of Discovery Technologies at Ansaris, where he was a member of the executive leadership team and responsible for the company’s proprietary fragment-based design technology platform.  Prior to joining Ansaris, he led modeling groups at the Springhouse, PA and La Jolla, CA research sites of Johnson & Johnson, where he and his team made significant contributions to discovery programs in neuroscience, oncology, pain, and cardiovascular disease.  Dr. Reynolds began his career at Rohm and Haas (now Dow) where his scientific accomplishments were recognized with the company’s highest science award, the Otto Haas Award.  He has held a variety of leadership positions in the American Chemical Society (ACS), and was recently named a Fellow of the ACS.  Some of his other awards include The Standards of Leadership Award (J&J) and Excellence in Science Award (J&J).
Dr. Reynolds earned a BA, with honors, from Austin College and PhD from the University of Texas at Austin.  He was an adjunct professor at the University of Pennsylvania and has supervised joint graduate and postdoctoral students at the Pennsylvania State University and the University of North Carolina at Chapel Hill. He has published approximately 100 papers, patents, and book chapters, and is a co-editor of two books.  His comments on drug discovery have been sought by news organizations ranging from C&E News to the Wall Street Journal.

00:00 - 00:00 DAY ONE (16-Oct)
15:30 - 17:00 Registration & Reception
17:00 - 17:15 Opening Comments
17:15 - 19:00 Discovery Re-Invented
Session Chair C.Reynolds
17:15 - 18:00 Steve Young
Retired VP Merck & Co
HIV Integrase Inhibitors: The Chemistry Behind The Discovery of Isentress
18:00 - 18:30 James Breitenbucher
Dart Neuroscience
Drug Discovery – What really needs to be “Re-Invented”?
18:30 - 19:00 Bart DeCorte
Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Incubator – A Novel Business Model to Spark Internal Innovation
19:00 - 20:00 Group Dinner
20:00 - 22:00 Novel Pharma Approaches
Session Chair P. Lam
20:00 - 20:30 Patrick Lam
Lam Drug Discovery Consulting LLC
Discovery of Eliquis®/Apixaban, a novel FXa anticoagulant
20:30 - 21:00 Serge Boulet
Eli Lilly and Company
Phenotypic Drug Discovery of Novel Anti-Angiogenics
21:00 - 21:30 Gabor Butora
Merck
Chemically Modified Oligonucleotides for RNAi
21:30 - 22:00 Michael Trzoss
Trius Therapeutics
Novel GyrB/ParE Inhibitors
00:00 - 00:00 DAY TWO (17-Oct)
08:00 - 12:30 Collaborative Drug Discovery I
Session Chair J. Vacca and B. Kinney
08:00 - 08:45 Michael Foley
Broad Institute
TBA
08:45 - 09:15 Craig Thomas
National Center for Advancing Clinical and Therapeutic Sciences
Associative Data Profiles Connect Basic Research to Translational Efforts
09:15 - 09:45 Todd Chappell
BioHealth Innovation, Inc.
Entrepreneurs-in-Residence, Not Just for Venture Capitalists
09:45 - 10:15 James Barrow
Lieber Institute
Genetics-Driven Psychiatry Drug Discovery
10:15 - 10:30 Greg Miknis
Colorado Center for Drug Discovery
Promoting Colorado Drug Discovery Research: Creation of the Colorado Center for Drug Discovery (C2D2)
10:30 - 11:00 Refreshments
11:00 - 11:30 Joseph Vacca
WuXi Apptec
Drug Discovery in the 21st Century
11:30 - 12:00 Zhengying Pan
Peking University, Shenzhen Graduate School
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
12:00 - 12:15 Barry Bunin
Collaborative Drug Discovery
Collaborative Drug Discovery Technology Neglected, Infectious, CNS, and Repositioning Applications
12:15 - 12:30 Olanrewaju Omobuwajo
Niger Delta University
Fertility reducing effect of pandanus candelabrum p.beauv. Leaves in male wistar rats
12:30 - 16:30 Free Time
16:30 - 19:00 Natural Products
Session Chair M. Goetz
16:30 - 16:45 Michael Goetz
NPDI-IHVR
The Natural Products Discovery Institute. Classical and novel approaches to drug discovery
16:45 - 17:30 Sean Brady
Rockefeller University
Watch where you step, there is new chemistry everywhere
17:30 - 18:00 Jef De Brabander
UT Southwestern Medical Center
Opportunities for Lead Discovery in a Biomedical Research Environment
18:00 - 18:20 Guy Carter
Biosortia Pharmaceuticals
A deep dive into aquatic microbial consortia for drug discovery
18:20 - 18:40 Jetze Tepe
Michigan State University
Non-competitive regulation of the human proteasome by natural products and natural product inspired scaffolds
18:40 - 19:00 Phil Cox
Noramco
Development of poppy varieties to suit changing market requirements
19:00 - 20:00 Group Dinner
20:00 - 22:00 Poster Session & Cocktail Reception
00:00 - 00:00 DAY THREE (18-Oct)
-Free Morning-
12:00 - 12:45 Group Lunch
12:45 - 16:30 Structure, Modelling & Informatics
Session Chair C.Reynolds
12:45 - 13:30 William Jorgensen
Yale University
Drug Discovery Accelerated by Computational Methods
13:30 - 14:00 Kenneth Merz
University of Florida
Blurring to Bring Binding Free Energies into Focus
14:00 - 14:30 Chris Williams
Chemical Computing Group
Water Placement - Application of 3D-RISM to structure-based drug design
14:30 - 14:45 Christopher Reynolds
University of Essex
Unravelling similarities between class A and class B GPCRs through modelling and mutagenesis
14:45 - 15:00 Lance Westerhoff
QuantumBio Inc.
Quantum mechanics-based macromolecular x-ray refinement as an advanced method for the high throughput crystallography
15:00 - 15:30 Leah Frye
Schrodinger
Nimbus and Schrödinger Reinventing Drug Discovery: Rapid and Efficient Development of Acetyl-CoA Carboxylase Inhibitors
15:30 - 16:00 Paul Leeson
GlaxoSmithKline
Compound Quality: What Have We Learned?
16:00 - 16:30 Refreshments
16:30 - 19:30 Biologics & Non-traditional Therapeutics
Session Chair C. Reynolds
16:30 - 17:15 David Lowe
Aeglea
Targeting the Amino Acid Dependence of Cancer
17:15 - 17:45 Andreas Bader
Mirna Therapeutics
MRX34 – from bench to bedside
17:45 - 18:15 David Gorenstein
University of Texas HSC Houston
Next Generation X-Aptamers for Personalized Nanomedicine
18:15 - 18:45 Trevor Hallam
Sutro Biopharma
Rapid Design and Production of Homogeneous Best-in-Class Protein Therapeutics using Cell-Free Protein Expression
18:45 - 19:00 Ian Pottie
Mount Saint Vincent University
Developing an Imaging Agent for Cholinesterase Enzymes to Diagnose Alzheimer’s Disease
19:00 - 19:30 Refreshments
19:30 - 20:15 Foundation Support for Neglected Diseases
Session Chair L. Trundle
19:30 - 20:15 Omar Vandal
Bill & Melinda Gates Foundation
Technologies and partnerships in drug discovery for diseases of the developing world
20:30 - 00:00 *Gala Night, Group Photo & Poster Awards*
00:00 - 00:00 DAY FOUR (19-Oct)
09:00 - 15:15 Discovery Technologies
Session Chair B. Kinney
09:00 - 09:20 Dietmar Wolf
AnalytiCon Discovery, LLC
Novel Macrocyclic Libraries Evolved from Natural Product Technology Platforms
09:20 - 09:40 Prem Premsrirut
Mirimus, Inc
RNAi mouse models: Revolutionizing drug discovery in vivo
09:40 - 10:00 Philip Jones
MD Anderson Cancer Center
Institute for Applied Cancer Science, developing the next generation of oncology agents for targeted patient populations
10:00 - 10:30 Matthew Segall
Optibrium Ltd.
Finding and Applying Rules for Successful Drug Discovery
10:30 - 11:00 Refreshments
11:00 - 11:30 Janet Ralbovsky
University of Tennessee Research Foundation
Technology Transfer Re-invented: How is Academia Adapting to the Changes in Drug Discovery?
11:30 - 12:00 Joel Dudley
Mount Sinai School of Medicine
Developing a Systematic Computational Approach to Identify Novel Drug Indication Relationships Using Public Gene Expression Profiles
12:00 - 12:45 Group Lunch
12:45 - 15:15 Collaborative Drug Discovery II
Session Chair B. DeCorte
12:45 - 13:15 Benjamin Blass
Moulder Center for Drug Discovery Research
Drug Discovery in the Academic Community
13:15 - 13:45 Mark McDonnell
Fox Chase Chemical Diversity Center Inc.
Riluzole prodrugs for melanoma and ALS
13:45 - 14:15 Sandhya Kortagere
Drexel University College of Medicine
Designing protein-protein interaction inhibitors as novel antimalarial chemotherapeutics
14:15 - 14:30 Peter Cheuka
University of Cape Town
Synthesis of aminomethylthiazole analogues for evaluation as antiplasmodial agents
14:30 - 15:00 Kris Josephson
Rapharma
Discovery of Potent Macrocyclic Peptides for Drug Development
15:00 - 15:15 Closing Remarks (Chairs & Fusion)

Plenary Speakers

  • Dr. Steven Young
    Consultant, Retired VP Merck & Co.
  • Dr. Michael Foley
    Director, Chemical Biology, Novel Therapeutics, Broad Institute
  • Prof. William Jorgensen
    Sterling Professor, Yale University
  • Dr Omar Vandal
    Program Officer, Discovery & Translational Sciences, Bill & Melinda Gates Foundation
  • Prof Sean Brady
    Prof, Rockefeller University
  • Dr David Lowe
    CEO, Aeglea BioTherapeutics

Invited Speakers

  • Dr. James Barrow
    Investigator, Lieber Institute
  • Professor Jef De Brabander
    Professor, UT Southwestern Medical Center
  • Dr. Benjamin Blass
    Assistant Professor, Temple University School of Pharmacy, Moulder Center for Drug Discovery Research
  • Dr. Michael Trzoss
    Principal Scientist II, Trius Therapeutics
  • Dr. Joseph Vacca
    Sr. Vice President, WuXi AppTec
  • Dr. Craig Thomas
    Chemistry Technolgoies Group Leader, National Center for Advancing Clinical and Therapeutic Sciences
  • Dr. David Gorenstein
    Assoc. Dean Research, Medical School, University of Texas HSC Houston
  • Dr Michael Goetz
    Director, NPDI, NPDI-IHVR
  • Dr. Leah Frye
    Vice President, Schrodinger
  • Dr. Zhengying Pan
    Research Fellow, Peking University, Shenzhen Graduate School
  • Dr. James Breitenbucher
    Director of Chemistry, Dart Neuroscience
  • Dr. Bart DeCorte
    Associate Scientific Director, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Professor Kenneth Merz
    Director, Institute for Cyber Enabled Research (iCER) and Joseph Zichis Chair in Chemistry , University of Florida
  • Dr. Aaron Sato
    VP Research, Sutro Biopharma
  • Mr. Todd Chappell
    Entrepreneur-in-Residence, BioHealth Innovation, Inc.
  • Dr. Sandhya Kortagere
    Assistant Professor, Drexel University College of Medicine
  • Dr. Andreas Bader
    Director - Research, Mirna Therapeutics
  • Dr. Patrick Lam
    Former Chemistry Director at BMS, Lam Drug Discovery Consulting, LLC
  • Dr. Janet Ralbovsky
    Licensing Associate , University of Tennessee Research Foundation
  • Dr. Serge Boulet
    Senior Research Scientist, Eli Lilly and Company
  • Dr. Mark McDonnell
    Senior Scientist, Fox Chase Chemical Diversity Center Inc.
  • Dr. Paul Leeson
    Consultant, GlaxoSmithKline
  • Dr. Matthew Segall
    CEO, Optibrium Ltd.
  • Dr. Guy Carter
    Chief Scientific Officer, Biosortia Pharmaceuticals
  • Dr. Chris Williams
    Principal Scientist , Chemical Computing Group
  • Dr. Gabor Butora
    Principal Scientist, Merck & Co.
  • Dr. Barry Bunin
    CEO, Collaborative Drug Discovery
  • Dr. Phillip Cox
    Chief Scientist, Noramco Inc
  • Dr. Kristopher Josephson
    Director, Ra Pharmaceuticals
  • x X X
    x, x

Sign In

Your feedback has been received.

  • P1000263
  • P1000264
  • P1000262
  • P1000261
  • hike group
  • P1000271
  • P1000269
  • 001
  • photo 4
  • photo 5
  • P1000268
  • DSCF0008
  • Squaw peak panorama
  • photo
  • photo 3
  • P1000283
  • P1000278
  • P1000277
  • P1000276
  • P1000275
  • P1000274
  • P1000359
  • P1000357
  • P1000293
  • P1000289
  • P1000292
  • P1000296
  • P1000354
  • P1000353
  • P1000352
  • P1000350
  • P1000349
  • P1000348
  • P1000347
  • P1000346
  • P1000345
  • P1000344
  • P1000343
  • P1000342
  • P1000341
  • P1000340
  • P1000339
  • P1000335
  • P1000317
  • P1000316
  • P1000315
  • P1000314
  • P1000313
  • P1000312
  • P1000311
  • P1000310
  • P1000309
  • P1000308
  • P1000306
  • P1000305
  • P1000304
  • P1000303
  • P1000302
  • P1000301
  • P1000300
  • P1000298
  • P1000294
  • P1000284
  • P1000287
  • P1000286
  • group ohot
  • P1000366

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired